United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$262.40 USD
+4.27 (1.65%)
Updated May 3, 2024 04:00 PM ET
After-Market: $262.41 +0.01 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$262.40 USD
+4.27 (1.65%)
Updated May 3, 2024 04:00 PM ET
After-Market: $262.41 +0.01 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth A Momentum A VGM
Zacks News
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Strength Seen in BioCryst (BCRX): Can Its 5.5% Jump Turn into More Strength?
by Zacks Equity Research
BioCryst (BCRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Why Is United Therapeutics (UTHR) Up 22.1% Since Last Earnings Report?
by Zacks Equity Research
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
United Therapeutics (UTHR) Gains on Tyvaso DPI Approval
by Zacks Equity Research
The FDA approves United Therapeutics' (UTHR) drug-device combination therapy, Tyvaso DPI, for PAH patients. It is a dry-powder inhalation formulation of Treprostinil. Stock gains 8.8%.
Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
United Therapeutics (UTHR) Q1 Earnings & Sales Beat, Stock Up
by Zacks Equity Research
United Therapeutics' (UTHR) first-quarter earnings and sales beat estimates. Higher sales of Orenitram and Tyvaso mainly drive the top line in the quarter.
United Therapeutics (UTHR) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
United Therapeutics (UTHR) delivered earnings and revenue surprises of 69.93% and 12.46%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
United Therapeutics (UTHR) to Report Q1 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
United Therapeutics (UTHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
UnitedHealth (UNH) to Post Q1 Earnings: What to Expect
by Zacks Equity Research
UnitedHealth Group's (UNH) first-quarter results are likely to reflect the benefits of improving premiums and products.
United Therapeutics (UTHR) Moves 3.1% Higher: Will This Strength Last?
by Zacks Equity Research
United Therapeutics (UTHR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Pacira's (PCRX) Q4 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Pacira's (PCRX) earnings surpass estimates in the fourth quarter of 2021 while revenues are slightly above estimates.
United Therapeutics (UTHR) Q4 Earnings & Sales Miss, Stock Down
by Zacks Equity Research
United Therapeutics (UTHR) fourth-quarter earnings and sales miss estimates. Higher sales of Tyvaso and Unituxin mainly drive the top line in the quarter, offset by lower sales of other drugs.
Down 14.1% in 4 Weeks, Here's Why You Should You Buy the Dip in United Therapeutics (UTHR)
by Zacks Equity Research
The heavy selling pressure might have exhausted for United Therapeutics (UTHR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
United Therapeutics (UTHR) Misses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
United Therapeutics (UTHR) delivered earnings and revenue surprises of -37.67% and 1.14%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Is United Therapeutics (UTHR) Stock a Suitable Value Pick Now?
by Zacks Equity Research
Let's see if United Therapeutics Corporation (UTHR) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
ImmunoGen (IMGN) Up on Licensing Deal With Lilly Worth $1.7 B
by Zacks Equity Research
ImmunoGen (IMGN) inks a licensing agreement with Eli Lilly, granting the latter rights to develop and commercialize ADCs directed toward targets selected by Lilly. Stock up.
Corcept's (CORT) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Corcept's (CORT) earnings beat estimates in the fourth quarter of 2021 while revenues miss the same.
United Therapeutics (UTHR) Down 6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
United Therapeutics (UTHR) Q3 Earnings & Sales Beat, Stock Up
by Zacks Equity Research
United Therapeutics (UTHR) third-quarter earnings and sales beat estimates. Higher sales of Orenitram and Tyvaso mainly drive the top line in the quarter.
United Therapeutics (UTHR) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
United Therapeutics (UTHR) delivered earnings and revenue surprises of 1.48% and 6.93%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
United Therapeutics' (UTHR) Tyvaso DPI NDA Gets CRL From FDA (Revised)
by Zacks Equity Research
United Therapeutics' (UTHR) new drug application for Tyvaso DPI to treat PAH & PH-ILD fails to secure approval from the FDA. The stock declines resultantly.
United Therapeutics' (UTHR) Tyvaso DPI NDA Gets CRL From FDA
by Zacks Equity Research
United Therapeutics' (UTHR) new drug application for Tyvaso DPI to treat PAH & PH-ILD fails to secure approval from the FDA. The stock declines resultantly.
United Therapeutics (UTHR) Up 3.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
United Therapeutics (UTHR) Q2 Earnings & Sales Beat, Stock Up
by Zacks Equity Research
United Therapeutics (UTHR) second-quarter earnings and sales beat estimates. Higher sales of Orenitram, Unituxin and Tyvaso mainly drive the top line in the quarter.